<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594878</url>
  </required_header>
  <id_info>
    <org_study_id>48438</org_study_id>
    <nct_id>NCT02594878</nct_id>
  </id_info>
  <brief_title>Chronic Non-bacterial Osteomyelitis Treated With Pamidronate</brief_title>
  <acronym>CNOPAM</acronym>
  <official_title>Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized double blind placebo controlled trial to investigate the effect of&#xD;
      pamidronate in treatment of chronic non bacterial osteomyelitis.&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
        1. Reduction of the inflammatory activity in the bone lesions measured by whole body MRI&#xD;
           after 36 weeks.&#xD;
&#xD;
        2. Healing of the inflammatory activity in the bone lesions measured by whole body MRI&#xD;
           after 36 weeks.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Changes in bone lesions in whole body MRI between baseline and week 12 and between week&#xD;
           12 and week 36&#xD;
&#xD;
        2. Changes in bone lesions of anterior chest-wall (adults) evaluated by CT scan between&#xD;
           baseline and week 36.&#xD;
&#xD;
        3. Changes in patient self reported outcome measures&#xD;
&#xD;
        4. Changes in inflammatory markers and bone markers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic non-bacterial osteomyelitis is a multifocal inflammatory bone disorder. The&#xD;
      pathogenesis is unknown. The disease is mainly diagnosed in childhood. There is a strong&#xD;
      association with inflammatory disorders of the skin, mainly psoriasis. The disease is&#xD;
      characterized by recurrent episodes of pain and disability. It is unclear if SAPHO syndrome&#xD;
      (synovitis, acne, pustulosis, hyperostosis, osteitis) might be the adult version of chronic&#xD;
      non-bacterial osteomyelitis. The disease can persist in adulthood and course chronic bone&#xD;
      deformations.&#xD;
&#xD;
      Wholebody MRI is the most sensitive imaging for diagnosing and monitoring the non bacterial&#xD;
      osteitis.&#xD;
&#xD;
      The treatment of chronic non-bacterial osteomyelitis is largely empiric. First line treatment&#xD;
      is NSAID (Non Steroidal Anti-Inflammatory Drug). When NSAID is inadequate the bisphosphonate&#xD;
      pamidronate has been described relief pain in small cohorts in retrospective studies.&#xD;
&#xD;
      In this research protocol, investigators seek to investigate if it is beneficial to use&#xD;
      pamidronate in the treatment of chronic non bacterial osteomyelitis and the osteitis&#xD;
      component in SAPHO syndrome. Primary outcome is whole body MRI. Secondary outcome is CT scan,&#xD;
      patient measure reported outcome and biomarkers. A biobank may help us to understand the&#xD;
      pathogenesis and future treatment targets of chronic non bacterial osteomyelitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wholebody MRI</measure>
    <time_frame>Changes between baseline and week 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT scan of the anterior chestwall (adults)</measure>
    <time_frame>Changes between baseline and week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic inflammatory markers</measure>
    <time_frame>Changes between baseline and week 1, 4, 12, 24 and 36</time_frame>
    <description>TNF- α,IL-1 β, IL-8, IL-18, IL-17, INF-ƴ, IL-6, IL-10, IL-11, IL-21, MIP 1-alfa (CCL3, 22) and IL-1Ra</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic bone markers</measure>
    <time_frame>Changes between baseline and week 1, 4, 12, 24 and 36</time_frame>
    <description>s-CTX og s-NTX, P1NP, C1NP, TRACP 5b, bone alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wholebody MRI</measure>
    <time_frame>Changes between baseline and week 12 and changes between week 12 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Health Assesment Questionnaire score</measure>
    <time_frame>Changes between baseline and week 1, 4, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Children Assesment Questionnaire score</measure>
    <time_frame>Changes between baseline and week 1, 4, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Visual Analog Score for pain</measure>
    <time_frame>Changes between baseline and week 1, 4, 12, 24 and 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Immune System Disease</condition>
  <condition>Musculoskeletal Disease</condition>
  <arm_group>
    <arm_group_label>Pamidronatdinatrium 3mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natrium chloride 9 mg/ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Natrium chloride 9 mg/ml volume equals experimental drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronatdinatrium</intervention_name>
    <arm_group_label>Pamidronatdinatrium 3mg/ml</arm_group_label>
    <other_name>Pamidronat, Pamifos, Aredia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natrium chloride 9mg/ml</intervention_name>
    <arm_group_label>Natrium chloride 9 mg/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 9-65 years (inclusive)&#xD;
&#xD;
          -  Fulfilling the diagnostic criteria for chronic non bacterial osteomyelitis:&#xD;
&#xD;
               1. Mono-, oligo- or multifocal inflammatory bone lesions (osteomyelitis, osteitis,&#xD;
                  osteosclerosis)&#xD;
&#xD;
               2. Diagnostic score according to A. Jansson criteria (2009) &gt; 39 or malignancy and&#xD;
                  infection excluded by biopsy&#xD;
&#xD;
               3. Symptoms &gt; 6 weeks&#xD;
&#xD;
          -  Volunteer, signed written informed content&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age older than 65 years&#xD;
&#xD;
          -  Age younger than 9 years&#xD;
&#xD;
          -  Pregnant women or nursing (breastfeeding) mothers&#xD;
&#xD;
          -  Hypersensitivity to pamidronate, bisphosphonate og additives in pamidronate&#xD;
&#xD;
          -  Known history or current lymphoproliferative disease&#xD;
&#xD;
          -  History of surgery on glandula thyroidea&#xD;
&#xD;
          -  Known alcohol/medical abuse&#xD;
&#xD;
          -  Poor dental status&#xD;
&#xD;
          -  Low Vitamin D- status&#xD;
&#xD;
          -  Liver/ kidney disease&#xD;
&#xD;
          -  Abnormal laboratory screening for comorbidity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Marie Andreasen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Aarhus, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Marie Andreasen, MD</last_name>
    <phone>+45 7846 4252</phone>
    <email>carand@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Margrethe Hauge, Professor</last_name>
    <phone>+45 7846 4252</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universityhospital of Aarhus, Denmark</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Marie Andreasen, MD</last_name>
      <phone>+4578464252</phone>
      <email>carand@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic non-bacterial osteomyelitis</keyword>
  <keyword>Chronic recurrent multifocal osteomyelitis</keyword>
  <keyword>Non- bacterial osteomyelitis</keyword>
  <keyword>SAPHO syndrome</keyword>
  <keyword>Whole body MRI</keyword>
  <keyword>Pamidronate</keyword>
  <keyword>Inflammatory bone disease</keyword>
  <keyword>Autoinflammatory disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomyelitis</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

